News

Dr Reddy's Q4 Results: Earnings beat estimates, margin expands; declares dividendFor the quarter, EBITDA jumped 58.9% to ₹2,975 crore, while margin expanded by 510 basis points from last year to 29.1%.By Meghna Sen   May 9, 2025, 5:18:24 PM IST (Updated)1 Min ReadHyderabad-based drugmaker Dr Reddy's Laboratories reported its March quarter results on Friday, May 9, which were a beat on analyst expectations on all parameters.

Dr Reddy's Laboratories' net profit for the fourth quarter rose 22% year-on-year to ₹1,594 crore, compared to ₹1,307 crore in the same quarter a year ago. The figure was also higher than CNBC-TV18 poll expectations of ₹1,491.6 crore.

Revenue for the quarter grew by 8.6% on a YoY basis to ₹8,506 crore, which is higher than last year's ₹7,830 crore and CNBC-TV18's estimate of ₹8,404.7 crore.

Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter jumped 58.9% to ₹2,975 crore. The number was higher than the CNBC-TV18 poll of ₹2,323.7 crore.

EBITDA margin for the quarter expanded by 510 basis points from last year to 29.1%, higher than the poll projection of 28%.

The board of Dr Reddy's Laboratories has recommended a final dividend of ₹8 per share of ₹1 each face value for the financial year 2024-25.

Record date for the said dividend has been fixed as July 10, the company said in an exchange filing.

Ahead of the Q4 earnings announcement, shares of Dr Reddy's Laboratories Ltd. settled 0.88% higher at ₹1,158.10. The stock is down over 15% so far in 2025.Continue ReadingFirst Published: May 9, 2025 5:12 PM ISTCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsDr Reddy's LaboratoriesDr Reddy's Labsearnings